Results 211 to 220 of about 88,229 (302)

Efficacy and safety of European Medicines Agency (EMA)‐approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta‐analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 358-378, January 2026.
Abstract Aims We aimed at comparing different approved strategies (obesity management medications—OMM, endoscopic bariatric procedures—EBP, and metabolic bariatric surgery—MBS) with lifestyle intervention/placebo/no therapy (LSI/Pbo/NT) for the treatment of different BMI‐based classes of obesity (i.e., overweight—BMI: 25–29.9 kg/m2; class I—BMI: 30–34 ...
Rocco Barazzoni   +10 more
wiley   +1 more source

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease–Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis‐Stimulating Agent Dose

open access: yesHemodialysis International, Volume 30, Issue 1, Page 80-100, January 2026.
ABSTRACT Introduction Erythropoiesis‐stimulating agents (ESAs) and iron supplementation are standard treatments for chronic kidney disease (CKD)–related anemia. Targeting higher hemoglobin values in CKD increases cardiovascular risk. Whether the increased risk is from higher ESA doses or higher hemoglobin levels is uncertain, but alternative therapies ...
Alan Jardine   +9 more
wiley   +1 more source

Systematic review and meta‐analysis of the efficacy and safety of [177Lu]Lu‐edotreotide ([177Lu]Lu‐DOTATOC) for the treatment of neuroendocrine tumors

open access: yesJournal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract [177Lu]Lu‐edotreotide is a radiopharmaceutical therapy (RPT) targeting somatostatin receptors, which are commonly overexpressed on neuroendocrine tumors (NETs). This systematic literature review and meta‐analysis describes the efficacy and safety of [177Lu]Lu‐edotreotide in patients with NETs.
Richard P. Baum   +11 more
wiley   +1 more source

Comparative Efficacy and Safety of Intralesional MMR Vaccine and Vitamin D3 in Managing Nongenital Warts: A Systematic Review and Meta‐Analysis

open access: yesJournal of Cosmetic Dermatology, Volume 25, Issue 1, January 2026.
ABSTRACT Background Cutaneous warts are common benign lesions caused by human papillomavirus and often resist conventional treatments. Intralesional immunotherapy with measles–mumps–rubella (MMR) vaccine or vitamin D3 has emerged as an alternative, but their comparative efficacy and safety remain unclear.
Rahul Balach   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy